Kymera Therapeutics: Funding, Investors & Team (Sep 2026)
Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation. It features a proprietary predictive modeling degradation platform with a novel small molecule modality to accelerate the drug discovery designed for disease-causing proteins.
Kymera Therapeutics has raised $854M across 3 funding rounds on record, the most recent an undisclosed round of $602M announced in Dec 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Kymera Therapeutics Company Profile and Key Stats
Latest funding round on record: Dec 2025.
Kymera Therapeutics Funding Rounds
Kymera Therapeutics raised $102M in an undisclosed round announced in Mar 2020.
2.4 years later, a Post-IPO Equity of $150M was announced in Aug 2022.
3.3 years later, an undisclosed round of $602M was announced in Dec 2025.
Kymera Therapeutics Founders and Leadership Team
Contact details for the Kymera Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Kymera Therapeutics Funding Compared to Other Biotechnology Startups
Kymera Therapeutics' latest round of $602M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Kymera Therapeutics in Biotechnology and Cambridge
Companies Similar to Kymera Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Kymera Therapeutics Funding FAQs
What does Kymera Therapeutics do?
Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation. It features a proprietary predictive modeling degradation platform with a novel small molecule modality to accelerate the drug discovery designed for disease-causing proteins.
How much funding has Kymera Therapeutics raised?
Kymera Therapeutics has raised $854M across 3 rounds on record. The most recent is an undisclosed round of $602M announced in Dec 2025.
When did Kymera Therapeutics last raise funding?
Kymera Therapeutics' most recent funding round on record is an undisclosed round of $602M, announced in Dec 2025.
Who is the CEO of Kymera Therapeutics?
Nello Mainolfi is listed as CEO at Kymera Therapeutics.
Where is Kymera Therapeutics headquartered?
Kymera Therapeutics is based in Cambridge, Massachusetts, United States.
How many employees does Kymera Therapeutics have?
Kymera Therapeutics is in the 101-250 employee band.
How does Kymera Therapeutics' funding compare to other Biotechnology startups?
Kymera Therapeutics' latest round of $602M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Kymera Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Kymera Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.